Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 14/20 | 0.37 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3345403 | 0.88 | ITK (0.40) | AXLITKPAK1DYRK1ACDC7 | |
| SCHEMBL3340007 | 0.79 | CDC7 (0.40) | ITKGSK3BDYRK1AMAPK1CDC7 | |
| SCHEMBL3345643 | 0.74 | CDC7 (0.51) | GSK3BDYRK1AMAPK1CDC7 | |
| SCHEMBL3330960 | 0.73 | PIM1 (0.51) | GSK3BPAK1DYRK1ACDC7 | |
| SCHEMBL3340582 | 0.73 | PIM1 (0.41) | GSK3BDYRK1AMAPK1CDC7 | |
| SCHEMBL3331234 | 0.73 | PIM1 (0.50) | GSK3BCDC7 | |
| SCHEMBL13305146 | 0.72 | PIM1 (0.51) | GSK3BDYRK1AMAPK1CDC7 | |
| SCHEMBL3331131 | 0.69 | PIM1 (0.48) | GSK3BCDC7 | |
| SCHEMBL5427424 | 0.69 | CDC7 (0.61) | GSK3BDYRK1AMAPK1CDC7 | |
| SCHEMBL11915765 | 0.66 | PIM1 (0.47) | GSK3BPAK1CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074114-A1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008143759-A1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |